• Sat. Jun 3rd, 2023

SNIPR Biome further strengthens CRISPR/Cas IP portfolio with patent grant


Dec 22, 2022
SNIPR Biome ApS (“SNIPR” or “the Company”), the company pioneering CRISPR-based microbial gene therapy, announces today the grant of a new patent by the US Patent and Trademark Office (USPTO). This patent represents a further addition to the Company’s extensive intellectual property portfolio, comprising more than 60 granted patents worldwide covering SNIPR’s technology platform, which enables editing of prokaryotes using CRISPR/Cas.

Read More